Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it…

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

LabNews Media LLC

Os Editores Principais da labnews.ai são Marita Vollborn e Vlad Georgescu. São autores de best-sellers, escritores de ciência e jornalistas de ciência desde 1994.Mais detalhes sobre a sua escrita em X-Press Journalistenbüro (https://xpress-journalisten.com).Mais informações na Wikipédia:Sobre Marita: https://de.wikipedia.org/wiki/Marita_Vollborn Sobre Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu

Ver Biografia Completa

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

LabNews Media LLC

Mantenha-se Conectado

Reportagem inigualável

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

LabNews Media LLC

Artigos Semelhantes

40 graus: Onda de calor mortal atinge Portugal

Farinha de algas melhora bolachas sem glúten

Via imunitária específica de género descoberta no glioblastoma

Mantenha-se Conectado

Reportagem inigualável